{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-044353","form_type":"8-K","ticker":null,"cik":"0001797768","company_name":"Kinnate Biopharma Inc.","filed_at":"2023-09-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.278810+00:00","generated_at":"2026-06-10T15:04:22.571852+00:00","sec_items":["2.02","9.01","2.05","7.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Kinnate cuts workforce 70%, reprioritizes pipeline; cash runway into Q2 2026","bullets":["Workforce reduction of ~70% to 28 employees; China subsidiary Kinnjiu separation.","One-time severance cost ~$2.0M in Q3 2023; plan completion expected in Q4 2023.","Cash $204.3M as of June 30, 2023; expected runway into at least Q2 2026.","Exarafenib combo in NRAS mutant melanoma: 38% ORR; two doses to be selected in Q4 2023.","KIN-8741 IND filing and CDK4 candidate nomination planned for Q4 2023; KIN-7136 paused."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-044353","json":"https://secwatch.observer/filing/0001140361-23-044353.json","markdown":"https://secwatch.observer/filing/0001140361-23-044353.md","text":"https://secwatch.observer/filing/0001140361-23-044353.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1797768/000114036123044353/0001140361-23-044353-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1797768/000114036123044353/ef20010841_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T15:04:22.571852+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f5e3cfbb9e364e5e7999ca7ee6103644ca2a0ea4","claim":"Kinnate Biopharma Inc. updated its as of June 30, 2023 guidance (initiated).","evidence_excerpt":"Cash, cash equivalents and investments of $204.3 million as of June 30, 2023, anticipated to fund operations into at least the second quarter of 2026","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797768/000114036123044353/0001140361-23-044353-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"as of June 30, 2023"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"c885b881a6fafb61eff9329bd157a0c6318ec8b7","claim":"Kinnate Biopharma Inc. announced a restructuring with charges of approximately $2.0 million (approximately 70%).","evidence_excerpt":"Kinnjiu Biopharma. The Company initiated the Plan effective September 18, 2023. In connection with this Plan, the Company expects to incur one-time costs of approximately $2.0 million, primarily in the third quarter of 2023, relating to severance and related benefits. Cash payments related to these expenses will be paid out, and the Plan is expected to be","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797768/000114036123044353/0001140361-23-044353-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $2.0 million"},{"label":"Headcount","value":"approximately 70%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}